Eurobio Oncology
Ressources for Performing Laboratories
Welcome to the EndoPredict® Performing Laboratories Hub
This page is for laboratories that currently perform EndoPredict testing. Here you’ll find technical resources and guidance for authorized EndoPredict labs.
As a valued EndoPredict partner laboratory, you play a crucial role in helping clinicians worldwide make confident, evidence-based decisions in breast cancer treatment.1-12
We're Here to Support You
The EndoPredict Kit Support Team is available to provide expert guidance and practical assistance whenever needed. We are here to support laboratories in ensuring smooth implementation and reliable performance of EndoPredict.
Our team can assist you with:
- Test procedure guidance – including handling steps and workflow setup
- Troubleshooting - Support with testing issues
- Documentation-related questions (e.g. IFUs, SDS)
Documents and Downloads
To support your daily operations and ensure the highest standards in test performance, we provide all key documents in one place:
Instructions for Use (IFU) & Safety Data Sheets (SDS)
- Available in multiple languages
- Include comprehensive handling instructions, kit protocols, and safety guidance
- Regularly updated to reflect the latest regulatory and technical standards
EPRG Report Generator
Existing laboratory partners can upload measured gene expression data via the EndoPredict Report Generator (EPRG) to create two standardized result documents.
How to Order EndoPredict® Kits
Pathologists who are already trained and set up to perform the EndoPredict test in their own laboratories can order EndoPredict kits directly. Please note that kits are available only for laboratories with established implementation and trained personnel!
Performing laboratories can place orders via the email addresses listed below. All order numbers, forms, and procedures were provided during the official implementation process.
orders-FR@eurobio-scientific.de
orders-DE@eurobio-scientific.de
orders-AT@eurobio-scientific.de
orders-CH@eurobio-scientific.de
orders-INT@eurobio-scientific.de
References
- Loibl S. et al.: Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023
- Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin. Cancer Res. 2011
- Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019
- Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019
- Buus R. et al.: Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016
- Sestak I. et al.: Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018
- Constantinidou A. et al.: Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer. Clin. Cancer Res. 2022
- Sestak I. et al.: Prognostic Value of EndoPredict in Women with Hormone Receptor Positive, HER2-Negative Invasive Lobular Breast Cancer. Clin Cancer Res. 2020
- Klein, E. et al.: Long-term outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor positive, HER2-negative early breast cancer. Breast Cancer Res Treat. 2024
- Schmitt, W. D. et al.: Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict: Results from the Charité registry. SABCS 2022
- Vázquez-Juarez D. et al.: Follow-up of prospective cohort of Mexican premenopausal women with breast cancer who received guided adjuvant treatment with the EndoPredict assay. SABCS 2021
- Jung et al.: Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer. Breast Care 2022
